Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1R Agonist Treatment for Opioid Use Disorder
NCT06548490Phase 2Recruiting
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Jan 2025
- Primary completion
- Apr 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in opioid use disorder (OUD) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Number of participants being abstinent from illicit and nonprescribed opioids at 13 weeks. Started Jan 2025; status: recruiting.
02
Drugs
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06548490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548490.